US › Healthcare

Valneva SE ADR (VALN)

US · Healthcare · Biotechnology

$5.14+1.38%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$30.9M

Revenue YoY

-37.2%

Net profit

$-32.1M

Profit YoY

-247.4%

EPS

$-0.42

EPS estimate

$-0.21

Net margin

-103.8%

EPS came in at -0.42 against a street estimate of -0.21 — a miss of 100.0%.

Key statistics

Market cap

$517.7M

Forward P/E

666.7

P/B

5.87

Book value

$0.98

EPS (TTM)

$-1.86

52-week high

$12.25

52-week low

$4.75

50-day MA

$5.38

200-day MA

$7.83

Beta

1.41

Analyst view

Analysts rate Valneva SE ADR a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $12.20.

Shareholding

Institutions

3.62%

Largest institutional holders

Fund	Stake
Frazier Life Sciences Management, L.P.	2.24%
Novo A/S	1.04%
General American Investors Co Inc	0.35%
Wells Fargo & Co	0.08%
Morgan Stanley - Brokerage Accounts	0.05%
Ironwood Investment Management LLC	0.02%
HRT FINANCIAL LLC	0.02%
OLD MISSION CAPITAL LLC.	0.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Valneva SE ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.